Vertex Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 34.05
Dividend & YieldN/A$ (N/A)
Beta 0.43
Market capitalization 81.2B
Operating cash flow 4.05B
ESG Scores 23.1

Company description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 36.55M -22.8M 51.3M 31.9M
Total Cashflows From Investing Activities -202.16M -1.24B 99.4M -340.9M
Net Borrowings -12.55M -29.2M -29M -24.4M
Total Cash From Financing Activities -71.22M 126.8M -505.3M -1.48B
Change To Operating Activities 341.58M 246.3M 249.7M 230.4M
Issuance Of Stock 289.29M 343.2M 264.9M 102M
Net Income 2.1B 1.18B 2.71B 2.34B
Change In Cash 990.73M 462.4M 2.87B 811.2M
Effect Of Exchange Rate -6.18M 1.6M 20.6M -13.4M
Total Cash From Operating Activities 1.27B 1.57B 3.25B 2.64B
Depreciation 72.42M 106.9M 109.5M 125.6M
Change To Account Receivables -108.15M -225.6M -223.4M -274.7M
Other Cashflows From Financing Activities 2.08M 4.8M -1.8M 5.7M
Change To Netincome -1.14B 351.7M 486.7M 281M
Capital Expenditures -95.45M -75.4M -259.8M -235M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax 600.24M 1.39B 3.12B 2.73B
Net Income 2.1B 1.18B 2.71B 2.34B
Selling General Administrative 557.62M 658.5M 770.5M 840.1M
Gross Profit 1.22B 1.86B 3.64B 3.62B
Ebit 663.97M 1.2B 2.87B 2.78B
Operating Income 663.97M 1.2B 2.87B 2.78B
Interest Expense -72.47M -58.5M -58.2M -61.5M
Income Tax Expense -1.49B 218.1M 405.2M 388.3M
Total Revenue 3.05B 4.16B 6.21B 7.57B
Cost Of Revenue 1.83B 2.3B 2.57B 3.96B
Total Other Income ExpenseNet -63.73M 192.9M 247.5M -48.6M
Net Income From Continuing Ops 2.09B 1.18B 2.71B 2.34B
Net Income Applicable To Common Shares 2.1B 1.18B 2.71B 2.34B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.81B 2.23B 3.06B 3.33B
Total Stockholder Equity 4.44B 6.09B 8.69B 10.1B
Other Current Liabilities 88.42M 152.3M 368.7M 399.5M
Total Assets 6.25B 8.32B 11.75B 13.43B
Common Stock 2.55M 2.59M 2.6M 2.5M
Other Current Assets 23.93M 17.73M 79.7M 187.2M
Retained Earnings -2.99B -1.85B 858.7M 3.2B
Treasury Stock 659k -1.97M -68.5M 15.9M
Cash 2.65B 3.11B 5.99B 6.79B
Total Current Liabilities 1.12B 1.33B 1.88B 2.14B
Other Stockholder Equity 659k -1.97M -68.5M 15.9M
Property, Plant, and Equipment 812M 833.28M 1.28B 1.42B
Total Current Assets 3.84B 4.82B 8.13B 9.56B
Net Tangible Assets 4.38B 4.68B 7.28B 8.7B
Net Receivables 409.69M 633.52M 885.4M 1.14B
Accounts Payable 110.99M 87.61M 155.1M 195M


Insider Transactions

Here are the insider transactions of stock shares related to Vertex Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
ALTSHULER DAVIDSale at price 308.61 per share.D2022-11-15Officer34
ALTSHULER DAVIDSale at price 299.72 - 306.57 per share.D2022-11-07Officer1.3k
ALTSHULER DAVIDConversion of Exercise of derivative security at price 187.53 per share.D2022-11-07Officer1.3k
SANNA BASTIANOSale at price 310.10 - 317.77 per share.D2022-11-02Officer320
BHATIA SANGEETA NSale at price 310.00 per share.D2022-10-24Director621
SANNA BASTIANOSale at price 300.02 - 301.84 per share.D2022-10-18Officer1.79k
BILLER JONATHAN PRIMStock Award(Grant) at price 0.00 per share.D2022-09-19Officer5.29k
ARBUCKLE STUART ASale at price 300.30 - 305.38 per share.D2022-08-15Chief Operating Officer22.17k
ARBUCKLE STUART AConversion of Exercise of derivative security at price 155.57 per share.D2022-08-15Chief Operating Officer6.57k
KEWALRAMANI RESHMASale at price 305.06 per share.D2022-08-15Chief Executive Officer11.69k
LIU JOYSale at price 300.26 - 305.57 per share.D2022-08-15General Counsel3.75k
ARBUCKLE STUART ASale at price 300.32 - 302.01 per share.D2022-08-10Chief Operating Officer180
ARBUCKLE STUART AConversion of Exercise of derivative security at price 155.57 per share.D2022-08-10Chief Operating Officer64
LIU JOYSale at price 300.32 per share.D2022-08-10General Counsel36
ARBUCKLE STUART ASale at price 300.53 - 301.42 per share.D2022-08-09Chief Operating Officer5.69k
ARBUCKLE STUART AConversion of Exercise of derivative security at price 155.57 per share.D2022-08-09Chief Operating Officer1.93k
TATSIS OURANIASale at price 297.54 - 301.67 per share.D2022-08-09Officer1.4k
LIU JOYSale at price 300.00 per share.D2022-08-09General Counsel946
ALTSHULER DAVIDSale at price 290.32 - 295.14 per share.D2022-08-08Officer1.3k
ALTSHULER DAVIDConversion of Exercise of derivative security at price 187.53 per share.D2022-08-08Officer1.3k
BHATIA SANGEETA NSale at price 290.18 - 295.53 per share.D2022-08-08Director621
BHATIA SANGEETA NSale at price 276.65 - 282.34 per share.D2022-07-29Director621
LEIDEN JEFFREY MSale at price 279.44 - 283.42 per share.D2022-07-25Officer and Director132.08k
LEIDEN JEFFREY MConversion of Exercise of derivative security at price 91.05 per share.D2022-07-25Officer and Director60.34k
KEWALRAMANI RESHMASale at price 291.30 per share.D2022-07-21Chief Executive Officer11.69k
ALTSHULER DAVIDSale at price 286.72 - 289.48 per share.D2022-07-19Officer17.86k
ALTSHULER DAVIDConversion of Exercise of derivative security at price 155.57 - 187.53 per share.D2022-07-19Officer17.77k
KEWALRAMANI RESHMASale at price 291.30 per share.D2022-06-24Chief Executive Officer11.69k
UPADHYAY SUKETU PStock Award(Grant) at price 0.00 per share.D2022-05-18Director1.56k
ARBUCKLE STUART ASale at price 246.21 - 254.19 per share.D2022-05-16Chief Operating Officer133
SANNA BASTIANOSale at price 250.56 - 254.44 per share.D2022-05-16Officer45
LIU JOYSale at price 250.77 - 254.36 per share.D2022-05-16General Counsel133
SANNA BASTIANOSale at price 275.09 per share.D2022-05-04Officer36
WAGNER CHARLES F JRSale at price 254.87 - 264.37 per share.D2022-05-02Chief Financial Officer343
ARBUCKLE STUART ASale at price 263.98 per share.D2022-05-02Chief Operating Officer306
BHATIA SANGEETA NSale at price 255.40 - 264.37 per share.D2022-05-02Director737
SANNA BASTIANOSale at price 255.47 - 264.37 per share.D2022-05-02Officer320
CARNEY LLOYD AStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.45k
KEARNEY TERRENCE CStock Award(Grant) at price 0.00 per share.D2022-04-29Director725
BHATIA SANGEETA NStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.45k
MCKENZIE DIANA LStock Award(Grant) at price 0.00 per share.D2022-04-29Director1.45k
LIU JOYSale at price 273.37 - 278.04 per share.D2022-04-29General Counsel120
AMBROSE KRISTENSale at price 267.37 - 271.68 per share.D2022-04-25Officer327
LEE YUCHUNSale at price 282.70 - 286.80 per share.D2022-04-18Director2k
LEE YUCHUNConversion of Exercise of derivative security at price 81.54 per share.D2022-04-18Director2k
LEE YUCHUNSale at price 287.87 - 291.18 per share.D2022-04-14Director2k
LEE YUCHUNConversion of Exercise of derivative security at price 81.54 per share.D2022-04-14Director2k
LEIDEN JEFFREY MSale at price 289.04 per share.D2022-04-13Officer and Director15.79k
LEE YUCHUNSale at price 279.22 - 291.12 per share.D2022-04-13Director4k
LEE YUCHUNConversion of Exercise of derivative security at price 81.54 per share.D2022-04-13Director4k
LEE YUCHUNSale at price 276.62 - 281.58 per share.D2022-04-11Director4k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Vertex Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Vertex Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Vertex Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Vertex Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Vertex Pharmaceuticals Inc:

Vertex Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -4.63% on the backtest period.

Performance at glance

Performance

-4.63 %

Latent gain

-97.99 $

Invested capital

2117.7 $

Annualized return

-1.12 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Vertex Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Vertex Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Vertex Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Vertex Pharmaceuticals Inc:

Vertex Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give -4.3% of return on Vertex Pharmaceuticals Inc. That represents -247.72$ of latent gain with 5756.02$ of employed capital.
  • The second momentum investment strategy would give 1.83% of return on Vertex Pharmaceuticals Inc. That represents 62.56$ of latent gain with 3426.03$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-4.3 %

Latent gain

-247.72 $

Invested capital

5756.02 $

Annualized return

-9.32 %
Performance at glance (2Q Momentum)

Performance

1.83 %

Latent gain

62.56 $

Invested capital

3426.03 $

Annualized return

0.5 %

Momentum equity curve on Vertex Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Vertex Pharmaceuticals Inc:

Vertex Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Vertex Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Vertex Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Vertex Pharmaceuticals Inc since the beginning:

Vertex Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Vertex Pharmaceuticals Inc

Buy the dip entry openings on Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

The performance achieved by the robo-advisor on Vertex Pharmaceuticals Inc is -19.94%. That represents -182.94$ of latent gain with 917.38$ of employed capital. The following chart shows Vertex Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Vertex Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-19.94 %

Latent gain

-182.94 $

Invested capital

917.38 $

Annualized return

-9.32 %

Equity curve of the strategy applied to Vertex Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Vertex Pharmaceuticals Inc:

Vertex Pharmaceuticals Inc

Note: the dividends potentially given by Vertex Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Vertex Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Vertex Pharmaceuticals Inc:

Vertex Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Vertex Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Vertex Pharmaceuticals Inc.

Equity curve comparison on Vertex Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Vertex Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc investment comparison

Performance comparison on Vertex Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -4.63% -97.99$ 2117.7$ -1.12%
Momentum 1 quarter -4.3% -247.72$ 5756.02$ -1.1%
Momentum 2 quarters 1.83% 62.56$ 3426.03$ 0.5%
Non-directional -19.94% -182.94$ 917.38$ -9.32%
Annualized return comparison

Automatic investment

-1.12 %

Momentum 1Q

0.5 %

Momentum 2Q

0.5 %

Non-directional

-9.32 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Vertex Pharmaceuticals Inc:

Positive correlations

Most correlated stocks this year

  • Vertex Pharmaceuticals Inc

  • Most correlated stocks last 3 months

  • Vertex Pharmaceuticals Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Vertex Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Vertex Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Vertex Pharmaceuticals Inc
    Country United States
    City Boston
    Address 50 Northern Avenue
    Phone 617 341 6100
    Website www.vrtx.com
    FullTime employees 3900
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker VRTX
    Market www.nasdaq.com

    Vertex Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0.7
    Peer Environment Performance 2.0330864197531
    Environment Percentile unknown
    Palm Oil no
    Nuclear no
    Fur Leather no
    GMO no
    Coal no
    Pesticides no
    Animal Testing yes

    Social scores

    Social ESG Factors Scores
    Social Score 15.2
    Peer Social Performance 14.299012345679
    Social Percentile unknown
    Highest Controversy 2
    Peer Highest Controversy Performance 1.8780487804878
    Adult no
    Gambling no
    Alcoholic no
    Tobacco no
    Catholic yes
    Controversial Weapons no
    Small Arms no
    Military Contract no
    Peer Count yes

    Related Controversy: Society & Community Incidents


    Governance scores

    Governance ESG Factors Scores
    Governance Score 7.2
    Peer Governance Performance 8.8141975308642
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: 23.1
    Environment Score: 0.7
    Social Score: 15.2
    Governance Score: 7.2

    ESG Performance: AVG_PERF

    Peer Group: Pharmaceuticals

    Peer Esg Score Performance: 25.306097560976

    Rating Year: 2022

    Rating Month: 8

    Max Age: 86400

    Percentile: 36